Showing results (1-10 of 148) with videos related to
Sort By:
Pageof 15
Annual Review of Pharmacology and Toxicology|January 1, 1997
The potential of farnesyltransferase inhibitors as cancer chemotherapeuticsJ B Gibbs, A OliffMethods in Molecular Biology (Clifton, N.J.)|July 17, 1998
Biochemical and biological analyses of farnesyl-protein transferase inhibitorsN E Kohl, K S Koblan, C A Omer, et al.Journal of Cellular Biochemistry. Supplement|January 1, 1995
Development of inhibitors of protein farnesylation as potential chemotherapeutic agentsN E Kohl, M W Conner, J B Gibbs, et al.Cancer Research|November 15, 1995
A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell linesL Sepp-Lorenzino, Z Ma, E Rands, et al.Current Opinion in Chemical Biology|August 1, 1997
Farnesyltransferase inhibitors versus Ras inhibitorsJ B Gibbs, S L Graham, G D Hartman, et al.Cancer Research|March 27, 1998
Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic miceR Mangues, T Corral, N E Kohl, et al.Medical and Pediatric Oncology|January 1, 1978
Characteristics of long-term survivors in AMLA Oliff, D PoplackMolecular and Cellular Biology|June 1, 1994
Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeletonG C Prendergast, J P Davide, S J deSolms, et al.Trends in Cell Biology|August 8, 2001
Signaling pathways in apoptosis as potential targets for cancer therapyP Huang, A OliffJournal of Virology|June 1, 1983
A 2.4-kilobase-pair fragment of the Friend murine leukemia virus genome contains the sequences responsible for friend murine leukemia virus-induced erythroleukemiaA Oliff, S RuscettiPageof 15